Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AGIO logo AGIO
Upturn stock ratingUpturn stock rating
AGIO logo

Agios Pharm (AGIO)

Upturn stock ratingUpturn stock rating
$38.18
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: AGIO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

9 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $47.67

1 Year Target Price $47.67

Analysts Price Target For last 52 week
$47.67 Target price
52w Low $23.41
Current$38.18
52w High $62.58

Analysis of Past Performance

Type Stock
Historic Profit -4.46%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.28B USD
Price to earnings Ratio 3.38
1Y Target Price 47.67
Price to earnings Ratio 3.38
1Y Target Price 47.67
Volume (30-day avg) 9
Beta 0.8
52 Weeks Range 23.41 - 62.58
Updated Date 08/28/2025
52 Weeks Range 23.41 - 62.58
Updated Date 08/28/2025
Dividends yield (FY) -
Basic EPS (TTM) 11.29

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-07-30
When Before Market
Estimate -1.81
Actual -1.93

Profitability

Profit Margin 1590.42%
Operating Margin (TTM) -1020.12%

Management Effectiveness

Return on Assets (TTM) -25.71%
Return on Equity (TTM) 64.05%

Valuation

Trailing PE 3.38
Forward PE 2.47
Enterprise Value 1391469611
Price to Sales(TTM) 55.82
Enterprise Value 1391469611
Price to Sales(TTM) 55.82
Enterprise Value to Revenue 34.04
Enterprise Value to EBITDA -2.33
Shares Outstanding 58101500
Shares Floating 51348379
Shares Outstanding 58101500
Shares Floating 51348379
Percent Insiders 1.68
Percent Institutions 109.89

ai summary icon Upturn AI SWOT

Agios Pharm

stock logo

Company Overview

overview logo History and Background

Agios Pharmaceuticals, founded in 2008, focused initially on cancer metabolism before expanding into rare genetic diseases. Key milestones include the FDA approvals of Tibsovo and Pyrukynd.

business area logo Core Business Areas

  • Oncology: Development and commercialization of therapies targeting cancer metabolism.
  • Rare Genetic Diseases: Development and commercialization of therapies for rare genetic diseases, particularly pyruvate kinase deficiency.

leadership logo Leadership and Structure

The leadership team includes the CEO, CFO, and heads of research and development. The organizational structure is typical of a biopharmaceutical company, with departments focused on research, clinical development, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • Pyrukynd (mitapivat): Pyrukynd is an oral allosteric activator of the RBC PK enzyme for pyruvate kinase (PK) deficiency. As of 2023, it held a significant portion of market share in PK deficiency treatments. Competitors: None with the same mechanism of action; supportive care and potential future gene therapies are alternatives. Revenue in 2023 was $130 million.
  • Tibsovo (ivosidenib): Tibsovo is an oral targeted therapy for acute myeloid leukemia (AML) with an IDH1 mutation. Tibsovo is now part of Servier's portfolio. Competitors: Enasidenib (Idhifa), chemotherapy, and other targeted therapies. Market share is relevant to the proportion of AML patients with IDH1 mutations.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, regulatory scrutiny, and competition. Recent trends include a focus on precision medicine and gene therapies.

Positioning

Agios is positioned as a leader in the development of therapies for rare genetic diseases and specific cancers, leveraging its expertise in cellular metabolism.

Total Addressable Market (TAM)

The TAM for Agios's current portfolio is estimated at several billion dollars, including PK deficiency and IDH1-mutated AML. Agios is positioned to capture a significant share of this market with its approved therapies.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic approaches
  • FDA-approved products
  • Strong expertise in rare genetic diseases
  • Solid financial position

Weaknesses

  • Reliance on a limited number of products
  • Competition from larger pharmaceutical companies
  • High R&D expenses
  • Regulatory hurdles

Opportunities

  • Expansion into new therapeutic areas
  • Strategic partnerships
  • Acquisition of new technologies
  • Further clinical development of existing products

Threats

  • Generic competition
  • Clinical trial failures
  • Changes in regulatory landscape
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • SNY
  • MRK
  • BMY

Competitive Landscape

Agios competes with larger pharmaceutical companies in certain therapeutic areas. Its competitive advantages include its expertise in rare genetic diseases and its novel therapeutic approaches. Sanofi, Merck, and Bristol Myers Squibb are competitors in the broader oncology space and potentially overlapping indications or future therapies.

Major Acquisitions

None

  • Year: 0
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: N/A

Growth Trajectory and Initiatives

Historical Growth: Agios's growth has been driven by the commercial success of Pyrukynd.

Future Projections: Analysts project continued revenue growth for Pyrukynd and expansion into new indications. Future growth depends on successful clinical trials and regulatory approvals.

Recent Initiatives: Recent initiatives include expanding the indications for Pyrukynd and investing in research and development of new therapies.

Summary

Agios Pharm is a biopharmaceutical company focused on rare genetic diseases and oncology with an FDA-approved product Pyrukynd that increases revenue. Its financial position is solid, but reliance on a limited number of products is a risk. Expansion into new therapeutic areas and strategic partnerships are key to future growth. Competition from larger pharmaceutical companies remains a significant challenge.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Agios Pharmaceuticals Investor Relations
  • SEC Filings
  • Analyst Reports

Disclaimers:

This analysis is based on publicly available information and analyst estimates and is for informational purposes only. It is not financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Agios Pharm

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2013-07-24
CEO & Director Mr. Brian M. Goff M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 486
Full time employees 486

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.